Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FTLF FitLife Brands	$14.10 +3.6%	$14.31	$9.83 ▼ $17.75	$132.79M	0.76	18,466 shs	11,601 shs
INMB INmune Bio	$2.61 +10.4%	$6.88	$1.89 ▼ $11.64	$59.67M	1.34	780,817 shs	4.70 million shs
NMRA Neumora Therapeutics	$0.81 +3.7%	$0.77	$0.61 ▼ $17.19	$132.89M	2.75	1.53 million shs	389,866 shs
RANI Rani Therapeutics	$0.54 +1.2%	$0.65	$0.46 ▼ $4.19	$30.78M	-0.02	831,297 shs	112,613 shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FTLF FitLife Brands	0.00%	+10.07%	-2.49%	+35.58%	-7.33%
INMB INmune Bio	0.00%	-51.13%	-64.56%	-64.17%	-67.40%
NMRA Neumora Therapeutics	0.00%	+7.15%	+0.11%	+10.12%	-91.69%
RANI Rani Therapeutics	0.00%	-2.54%	+1.72%	-55.54%	-85.69%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
FTLF FitLife Brands	4.0599 of 5 stars	3.7	3.0	0.6	3.3	3.1
INMB INmune Bio	1.5979 of 5 stars	3.3	0.0	2.0	1.7	0.6
NMRA Neumora Therapeutics	2.5805 of 5 stars	3.1	1.0	2.7	2.5	1.3
RANI Rani Therapeutics	1.4911 of 5 stars	3.5	1.0	0.0	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FTLF FitLife Brands	3.33	Buy	$20.50	45.39% Upside
INMB INmune Bio	2.57	Moderate Buy	$18.40	606.33% Upside
NMRA Neumora Therapeutics	2.22	Hold	$9.29	1,044.97% Upside
RANI Rani Therapeutics	3.00	Buy	$7.33	1,263.07% Upside

Current Analyst Ratings Breakdown

Latest RANI, INMB, NMRA, and FTLF Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/2/2025	INMB INmune Bio	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $8.00
7/1/2025	INMB INmune Bio	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral
7/1/2025	INMB INmune Bio	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sector Outperform ➝ Sector Underperform
6/30/2025	INMB INmune Bio	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Moderate Buy ➝ Hold
5/16/2025	RANI Rani Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$14.00 ➝ $4.00
5/13/2025	NMRA Neumora Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
4/10/2025	NMRA Neumora Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00

(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FTLF FitLife Brands	$64.47M	2.05	$1.01 per share	13.96	$3.93 per share	3.59
INMB INmune Bio	$10K	6,142.59	N/A	N/A	$1.45 per share	1.80
NMRA Neumora Therapeutics	N/A	N/A	N/A	N/A	$1.78 per share	N/A
RANI Rani Therapeutics	$1.03M	30.02	N/A	N/A	$0.06 per share	8.97

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FTLF FitLife Brands	$8.98M	$0.84	16.79	12.82	N/A	13.85%	25.59%	15.26%	N/A
INMB INmune Bio	-$42.08M	-$1.93	N/A	N/A	N/A	N/A	-119.35%	-89.37%	7/30/2025 (Estimated)
NMRA Neumora Therapeutics	-$243.79M	-$1.61	N/A	N/A	N/A	N/A	-84.79%	-77.57%	8/5/2025 (Estimated)
RANI Rani Therapeutics	-$30.02M	-$0.99	N/A	N/A	N/A	N/A	-1,258.76%	-80.52%	8/5/2025 (Estimated)

Latest RANI, INMB, NMRA, and FTLF Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	FTLF FitLife Brands	$0.24	$0.20	-$0.04	$0.20	N/A	N/A
5/13/2025	Q1 2025	RANI Rani Therapeutics	-$0.22	-$0.22	N/A	-$0.22	N/A	$0.20 million
5/12/2025	Q1 2025	NMRA Neumora Therapeutics	-$0.40	-$0.42	-$0.02	-$0.42	N/A	N/A
5/8/2025	Q1 2025	INMB INmune Bio	-$0.43	-$0.43	N/A	-$0.43	N/A	$0.05 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
FTLF FitLife Brands	N/A	N/A	N/A	N/A	N/A
INMB INmune Bio	N/A	N/A	N/A	N/A	N/A
NMRA Neumora Therapeutics	N/A	N/A	N/A	N/A	N/A
RANI Rani Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FTLF FitLife Brands	0.19	1.64	0.72
INMB INmune Bio	N/A	2.64	2.64
NMRA Neumora Therapeutics	N/A	8.98	8.98
RANI Rani Therapeutics	2.75	0.88	0.88

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FTLF FitLife Brands	2.32%
INMB INmune Bio	12.72%
NMRA Neumora Therapeutics	47.65%
RANI Rani Therapeutics	30.19%

Insider Ownership

Company	Insider Ownership
FTLF FitLife Brands	61.40%
INMB INmune Bio	35.70%
NMRA Neumora Therapeutics	26.80%
RANI Rani Therapeutics	53.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FTLF FitLife Brands	20	9.39 million	3.63 million	Not Optionable
INMB INmune Bio	10	23.58 million	15.17 million	Optionable
NMRA Neumora Therapeutics	108	161.75 million	118.40 million	Optionable
RANI Rani Therapeutics	110	57.48 million	26.84 million	Optionable

RANI, INMB, NMRA, and FTLF Headlines

Recent News About These Companies

Rani Therapeutics announces annual meeting results

May 30, 2025 | investing.com

Rani Therapeutics strikes deal to issue new warrants

May 21, 2025 | uk.investing.com

RANI: 1Q:25 Financial Results

May 20, 2025 | finance.yahoo.com

Rani Therapeutics Announces Research Agreement with Chugai

May 19, 2025 | globenewswire.com

Rani Therapeutics Reports First Quarter 2025 Financial Results; Provides Corporate Update

May 13, 2025 | globenewswire.com

Rani Therapeutics Faces Nasdaq Compliance Challenge

May 6, 2025 | tipranks.com

Stifel Nicolaus Remains a Buy on Trevi Therapeutics (TRVI)

April 23, 2025 | markets.businessinsider.com

Rani Therapeutics management to meet virtually with Lake Street

April 17, 2025 | markets.businessinsider.com

RANI: 2024 Financial Results

April 3, 2025 | finance.yahoo.com

Earnings call transcript: Rani Therapeutics sees stock drop despite narrowing losses in Q4 2024

April 2, 2025 | investing.com

Q4 2024 Rani Therapeutics Holdings Inc Earnings Call

April 1, 2025 | finance.yahoo.com

Rani Therapeutics reports Q4 EPS (27c), consensus (23c)

April 1, 2025 | markets.businessinsider.com

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Q4 2024 Earnings Call Transcript

April 1, 2025 | msn.com

Rani Therapeutics Reports 2024 Financial Results and Updates

March 31, 2025 | tipranks.com

Rani Therapeutics Holdings, Inc. (RANI) Q4 2024 Earnings Call Transcript

March 31, 2025 | seekingalpha.com

Rani Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Corporate Update

March 31, 2025 | globenewswire.com

An Overview of Rani Therapeutics Hldgs's Earnings

March 28, 2025 | benzinga.com

Stifel Nicolaus Reaffirms Their Buy Rating on Rani Therapeutics Holdings (RANI)

March 27, 2025 | markets.businessinsider.com

Rani announces pharmacokinetic, pharmacodynamic data from RT-114 trial

March 27, 2025 | markets.businessinsider.com

Rani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence of RT-114, a GLP-1/GLP-2 Dual Agonist (PG-102) Delivered Orally via the RaniPill® Capsule, to Subcutaneously Administered PG-102

March 26, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Iran Conflict Fuels Fertilizer Stocks’ Bullish Setup
By Gabriel Osorio-Mazilli | June 16, 2025
View Iran Conflict Fuels Fertilizer Stocks’ Bullish Setup
3 Nuclear ETFs to Watch as U.S. Policy Sparks a Surge
By Nathan Reiff | June 9, 2025
View 3 Nuclear ETFs to Watch as U.S. Policy Sparks a Surge

RANI, INMB, NMRA, and FTLF Company Descriptions

FitLife Brands NASDAQ:FTLF

$14.10 +0.49 (+3.60%)

As of 07/3/2025 01:30 PM Eastern

FitLife Brands, Inc. provides nutritional supplements for health-conscious consumers in the United States and internationally. The company provides weight loss, sports nutrition, and general health products; sports nutrition products; weight loss and sports nutrition products; sports nutrition and general wellness formulations with an emphasis on natural, vegan, and organic ingredients; and male health and weight loss products, as well as other diet, health, and sports nutrition supplements and related products; and value-oriented sports nutrition and weight loss products. It offers MRC products which includes general health supplements; and natural skincare and beauty products. In addition, it markets its products under the brand names of NDS Nutrition, PMD Sports, SirenLabs, CoreActive, Nutrology, Metis Nutrition, iSatori, BioGenetic Laboratories, Energize, Dr. Tobias, All-Natural Advice, and Maritime Naturals through franchised stores, as well as through retail locations, which include specialty, mass, and online. The company was formerly known as Bond Laboratories, Inc. and changed its name to FitLife Brands, Inc. in September 2013. FitLife Brands, Inc. was incorporated in 2005 and is headquartered in Omaha, Nebraska.

INmune Bio NASDAQ:INMB

$2.60 +0.25 (+10.38%)

Closing price 07/3/2025 03:57 PM Eastern

Extended Trading

$2.55 -0.06 (-2.11%)

As of 07/3/2025 04:58 PM Eastern

INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

Neumora Therapeutics NASDAQ:NMRA

$0.81 +0.03 (+3.68%)

Closing price 07/3/2025 03:14 PM Eastern

Extended Trading

$0.81 +0.00 (+0.25%)

As of 07/3/2025 04:56 PM Eastern

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.

Rani Therapeutics NASDAQ:RANI

$0.54 +0.01 (+1.17%)

Closing price 07/3/2025 03:53 PM Eastern

Extended Trading

$0.54 0.00 (0.00%)

As of 07/3/2025 04:55 PM Eastern

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time